The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors-Reference-Cited by-同舟云学术

The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors

Published:2019-03-13 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Coperchini Francesca,Croce Laura,Denegri Marco,Awwad Oriana,Ngnitejeu Samuel Tata,Muzza Marina,Capelli Valentina,Latrofa Francesco,Persani Luca^ORCID,Chiovato Luca,Rotondi Mario

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-40818-w.pdf

Reference38 articles.

1. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954, https://doi.org/10.1038/nature00766 (2002).

2. Crawford, S. et al. A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker. Mol Cancer Ther 7, 492–499, https://doi.org/10.1158/1535-7163.MCT-07-0307 (2008).

3. Elisei, R. et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93, 3943–3949, https://doi.org/10.1210/jc.2008-0607 (2008).

4. Fugazzola, L. et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 61, 239–243, https://doi.org/10.1111/j.1365-2265.2004.02089.x (2004).

5. Nucera, C., Lawler, J. & Parangi, S. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res 71, 2417–2422, https://doi.org/10.1158/0008-5472.CAN-10-3844 (2011).

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extra-nuclear TERT counteracts oxidative stress and promotes progression in papillary thyroid carcinoma;Translational Research;2024-09

2. Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro;Journal of Endocrinological Investigation;2024-06-20

3. Canagliflozin reduces thyroid cancer cells migration in vitro by inhibiting CXCL8 and CCL2: An additional anti-tumor effect of the drug;Biomedicine & Pharmacotherapy;2024-01

4. Utilizing CD44v6 and V600EBRAF-mutation for in vitro targeted combination therapy of thyroid carcinomas;Heliyon;2023-12

5. T‐cell exhaustion prediction algorithm in tumor microenvironment for evaluating prognostic stratification and immunotherapy effect of esophageal cancer;Environmental Toxicology;2023-07-26